Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Up 113.1% in February

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the recipient of a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 1,121,342 shares, a growth of 113.1% from the February 12th total of 526,150 shares. Based on an average trading volume of 2,712 shares, the short-interest ratio is currently 413.5 days. Based on an average trading volume of 2,712 shares, the short-interest ratio is currently 413.5 days.

Innovent Biologics Price Performance

IVBXF stock traded up $0.03 during midday trading on Thursday, hitting $10.53. 480 shares of the company’s stock were exchanged, compared to its average volume of 2,017. Innovent Biologics has a 1-year low of $5.00 and a 1-year high of $15.12. The business has a 50-day simple moving average of $10.78 and a two-hundred day simple moving average of $11.38.

About Innovent Biologics

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).